We are live on ! Find out more
HARP

Harpoon Therapeutics, Inc. Common Stock
HARP

Delisted

HARP was delisted on the 8th of March, 2024.

Back to rankings

42 hedge funds and large institutions have $196M invested in Harpoon Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

950% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 2

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

27% more funds holding

Funds holding: 33 → 42 (+9)

9% more capital invested

Capital invested by funds: $180M → $196M (+$15.4M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
42
Holders Change
+9
Holders Change %
+27.27%
% of All Funds
0.92%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
10
Increased
21
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.17M
2
EC
EcoR1 Capital
California
+$1.62M
3
Northern Trust
Northern Trust
Illinois
+$704K
4
BlackRock
BlackRock
New York
+$393K
5
Renaissance Technologies
Renaissance Technologies
New York
+$385K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$288K
2
Millennium Management
Millennium Management
New York
-$207K
3
Deutsche Bank
Deutsche Bank
Germany
-$35.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
MAM
1
MPM Asset Management
Massachusetts
$61.8M – – –
NLVP
2
New Leaf Venture Partners
New York
$39.9M – – –
O
3
OrbiMed
New York
$33.4M – – –
EC
4
EcoR1 Capital
California
$20M +$1.62M +11,500 +9%
CAM
5
Cormorant Asset Management
Massachusetts
$8.88M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$5.31M +$2.17M +15,457 +66%
SFM
7
Sphera Funds Management
Israel
$5.11M – – –
FI
8
Fosun International
China
$4.42M – – –
BlackRock
9
BlackRock
New York
$4.4M +$393K +2,794 +10%
DM
10
Deerfield Management
New York
$3.61M -$288K -2,050 -7%
BBA
11
Baker Bros. Advisors
New York
$2.93M – – –
State Street
12
State Street
Massachusetts
$1.47M +$338K +2,407 +29%
Northern Trust
13
Northern Trust
Illinois
$1.17M +$704K +5,009 +140%
Charles Schwab
14
Charles Schwab
California
$611K +$103K +732 +20%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$554K +$77K +548 +16%
Renaissance Technologies
16
Renaissance Technologies
New York
$374K +$385K +2,740 New
Goldman Sachs
17
Goldman Sachs
New York
$293K +$302K +2,145 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$257K +$264K +1,876 New
N
19
Nuveen
North Carolina
$215K +$221K +1,575 New
California State Teachers Retirement System (CalSTRS)
20
California State Teachers Retirement System (CalSTRS)
California
$154K +$30.5K +217 +24%
Wells Fargo
21
Wells Fargo
California
$106K +$7.03K +50 +7%
Barclays
22
Barclays
United Kingdom
$89K +$38.1K +271 +71%
Morgan Stanley
23
Morgan Stanley
New York
$86K +$77.6K +552 +681%
UBS Group
24
UBS Group
Switzerland
$78K +$65.1K +463 +437%
New York State Common Retirement Fund
25
New York State Common Retirement Fund
New York
$67K +$62.1K +442 +884%
1
2

HARP Hedge Fund Activity: Q3 2019 in Review

42 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q3 2019, worth a combined $196M — up 8.6% from $180M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new HARP positions and 1 closed out — a net gain of 9 holders — while 21 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.17M. The largest seller was Deerfield Management, cutting an estimated $288K.

  • 42 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q3 2019, up from 33 in Q2 2019.
  • Funds reported $196M of Harpoon Therapeutics, Inc. Common Stock stock for Q3 2019, up 8.6% quarter-over-quarter.
  • 10 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q3 2019 and 1 closed out, a net change of +9 holders.
  • The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q3 2019 was Vanguard Group, an estimated $2.17M added.
  • The largest Harpoon Therapeutics, Inc. Common Stock seller in Q3 2019 was Deerfield Management, an estimated $288K sold.

Based on aggregated 13F filings for Q3 2019.